Cargando…

Low-Dose 68 Ga-PSMA Prostate PET/MRI Imaging Using Deep Learning Based on MRI Priors

BACKGROUND: 68 Ga-prostate-specific membrane antigen (PSMA) PET/MRI has become an effective imaging method for prostate cancer. The purpose of this study was to use deep learning methods to perform low-dose image restoration on PSMA PET/MRI and to evaluate the effect of synthesis on the images and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deng, Fuquan, Li, Xiaoyuan, Yang, Fengjiao, Sun, Hongwei, Yuan, Jianmin, He, Qiang, Xu, Weifeng, Yang, Yongfeng, Liang, Dong, Liu, Xin, Mok, Greta S. P., Zheng, Hairong, Hu, Zhanli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8825350/ https://www.ncbi.nlm.nih.gov/pubmed/35155207 http://dx.doi.org/10.3389/fonc.2021.818329

Ejemplares similares

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

Gross tumor volume delineation in primary prostate cancer on (18)F-PSMA-1007 PET/MRI and (68)Ga-PSMA-11 PET/MRI
por: Zhang, Yan-Nan, et al.
Publicado: (2022)

Optimal MRI sequences for (68)Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer
por: Lake, Spencer T., et al.
Publicado: (2017)

Ga-68-PSMA PET/CT ? or PET/MRI ?, Mp-MRI ? in diagnosis and radiotherapy planning in a patient with prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Accuracy of (68)Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer
por: Barbosa, Álan Roger Gomes, et al.
Publicado: (2022)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
por: Zhou, Chuanchi, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

(68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data
por: Mapelli, Paola, et al.
Publicado: (2022)

[(68)Ga]Ga-PSMA and [(68)Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration
por: Ghezzo, Samuele, et al.
Publicado: (2023)

Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
por: Lütje, Susanne, et al.
Publicado: (2016)

False-positive mpMRI and true-negative (68)Ga-PSMA PET/CT xanthogranulomatous prostatitis: a case report
por: Tang, Yongxiang, et al.
Publicado: (2022)

Impact of PET acquisition durations on image quality and lesion detectability in whole-body (68)Ga-PSMA PET-MRI
por: Noto, Benjamin, et al.
Publicado: (2017)

(68)Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement
por: Ferraro, Daniela A., et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: Perspective of radiologist
por: Wang, Liwei, et al.
Publicado: (2020)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Lesion-to-background ratio threshold value of SUVmax of simultaneous [(68)Ga]Ga-PSMA-11 PET/MRI imaging in patients with prostate cancer
por: Zhao, Jing, et al.
Publicado: (2020)

Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [(68)Ga]Ga-PSMA-11 PET/MRI
por: Papp, L., et al.
Publicado: (2020)

Dynamic Contrast-Enhanced MRI of Prostate Lesions of Simultaneous [(68)Ga]Ga-PSMA-11 PET/MRI: Comparison between Intraprostatic Lesions and Correlation between Perfusion Parameters
por: Zhao, Jing, et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to(68)Ga-PSMA PET-CT
por: Meißner, Sebastian, et al.
Publicado: (2019)

Evaluation of (68)Ga-PSMA-11 PET-MRI in Patients with Advanced Prostate Cancer Receiving (177)Lu-PSMA-617 Therapy: A Radiomics Analysis
por: Roll, Wolfgang, et al.
Publicado: (2021)

(68)Ga-PSMA-11 PET/MRI: determining ideal acquisition times to reduce noise and increase image quality
por: Murthy, Vishnu, et al.
Publicado: (2020)

Radiomics Analysis on [(68)Ga]Ga-PSMA-11 PET and MRI-ADC for the Prediction of Prostate Cancer ISUP Grades: Preliminary Results of the BIOPSTAGE Trial
por: Feliciani, Giacomo, et al.
Publicado: (2022)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of (68)Ga-PSMA and (68)Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients
por: Mapelli, Paola, et al.
Publicado: (2021)

Correlation between genomic index lesions and mpMRI and (68)Ga-PSMA-PET/CT imaging features in primary prostate cancer
por: Kesch, Claudia, et al.
Publicado: (2018)

Prediction of clinically significant prostate cancer using a novel (68)Ga-PSMA PET-CT and multiparametric MRI-based model
por: Cheng, Chunliang, et al.
Publicado: (2023)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

Role of 68Ga-PSMA-PET/CT for the detection of primary prostate cancer prior to biopsy: a prospective study
por: Jain, Harsh, et al.
Publicado: (2021)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Incremental Impact of [(68) Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI
por: Szigeti, Florian, et al.
Publicado: (2021)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Histopathology-validated lesion detection rates of clinically significant prostate cancer with mpMRI, [(68)Ga]PSMA-11-PET and [(11)C]Acetate-PET
por: Sandgren, Kristina, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with (68)Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer
por: Ettala, Otto, et al.
Publicado: (2019)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

Direct Patlak Reconstruction of [(68)Ga]Ga-PSMA PET for the Evaluation of Primary Prostate Cancer Prior Total Prostatectomy: Results of a Pilot Study
por: Rasul, Sazan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_l46ueg235nq6qvle5pqu8iajg7